Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry and Bio-distribution of 203Pb-RMX-VH-PIB in Newly Diagnosed or Recurrent Patients With Solid Tumors
NCT07733674Phase 1Recruiting
- Sponsor
- RadioMedix
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 203Pb-RMX-VHPIB in glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC), sponsored by RadioMedix. Primary endpoints: Whole-body and organ-specific absorbed radiation dose at 144 hours and Organ-Specific Absorbed Dose at 144 hours. Started Aug 2026; status: recruiting.
02
Drugs
203Pb-RMX-VHPIB
03
Conditions
glioblastoma multiforme (GBM)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07733674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733674.